QPP remains at the heart of model based drug development. Short for Quantitative Pharmacology & Pharmacometrics, it refers to several types of quantitative modeling including meta-analysis, PK/PD, statistical modeling and the modeling of go-no-go decision rules. Cytel’s expert Quantitative Pharmacology and Pharmacometrics group delivers high quality solutions to help our customers get those...
Career Perspectives: Interview with Tina Checchio, Associate Director, Quantitative Pharmacology & Pharmacometrics
Posted by Cytel
Jan 30, 2019 6:30:00 AM
Topics: Clinical Research Services, Statistical Analysis, careers, clinical data management, clinical research, Data Management, Statistical Programming, quantitative decision-making, model-informed-drug-development, Early Phase Trials, Phase I, pharmacometrics, pharmacology
Nand Kishore Rawat is a Director and Head, Early Phase Biostatistics based in the King of Prussia, PA Cytel office. We recently spoke with Nand for the Cytel podcast to gain his thoughts on the unique aspects of Phase 1 development and where innovative approaches supported by thorough planning can meet these challenges head-on. Read on for key insights or listen to the podcast.
Topics: clinical research, clinical trials, biostatistics, Cytel Strategic Consulting, clinical development, Phase I, pharmacometrics, quantitative decision-making
Can Statisticians Contribute to Enhance the Position of Patients in Clinical Trials?
Posted by Cytel
Nov 12, 2018 8:04:00 AM
In this blog, we talk with Robert Greene, Founder and President of the HungerNDThirst Foundation, about his upcoming presentation at Cytel’s East User Group Meeting on 14th and 15th November at Merck in Darmstadt, Germany. Robert will bring a fresh perspective to the discussion of the role statisticians can play in enhancing the position of patients in clinical trials. Patient-centricity is a...
Topics: Adaptive Clinical Trials, Trial Design, phase 2, Program and Portfolio Optimization, Simulations, East, adaptive designs, Bayesian Methods, Phase I, biostatistics, Statistical Innovations in Clinical Development, randomization, patientricity
Selection Bias for Treatments with Positive Phase 2 Results with Simon Kirby
Posted by Cytel
Oct 18, 2018 11:09:00 AM
In this blog, we talk with Simon Kirby, former Senior Director at Pfizer, about his upcoming presentation at Cytel’s East User Group Meeting on 14th and 15th November at Merck Darmstadt, in Germany. Simon will address the topic of Selection Bias for Treatments with Positive Phase 2 Results and in this blog he explains why this is a key topic of particular relevance for pharmaceutical companies...
Topics: Adaptive Clinical Trials, Trial Design, phase 2, Program and Portfolio Optimization, Simulations, East, adaptive designs, Bayesian Methods, Phase I, go-no-go, biostatistics, Statistical Innovations in Clinical Development, randomization
Interview with Stephen Senn: 70 Years and Still Here: The Randomized Clinical Trial and its Critics
Posted by Cytel
Oct 5, 2018 7:00:00 AM
We are delighted that Stephen Senn will be joining us at the EUGM on November 14th and 15th in Darmstadt, Germany. In this blog, we sit down for a discussion with Stephen about his career in statistics, his advice for early career statisticians, his upcoming research, and the topic of his presentation at the East User Group Meeting “70 Years Old and Still Here: the Randomized Clinical Trial...
Topics: Adaptive Clinical Trials, Trial Design, phase 2, Program and Portfolio Optimization, Simulations, East, adaptive designs, Bayesian Methods, Phase I, go-no-go, biostatistics, Statistical Innovations in Clinical Development, randomization
Decision Making in Development Programs with Targeted Therapies: with Heiko Götte
Posted by Cytel
Sep 27, 2018 9:00:00 AM
In this blog, we talk with Heiko Götte, Senior Expert Biostatistician at Merck about his upcoming presentation at Cytel’s East User Group Meeting on 14th and 15th November at Merck Darmstadt, in Germany. The topic Heiko will address is Decision Making in Development Programs with Targeted Therapies and he explains to us why this is a key topic for pharmaceutical companies today as they...
Topics: Adaptive Clinical Trials, Trial Design, phase 2, Program and Portfolio Optimization, Simulations, East, adaptive designs, Bayesian Methods, Phase I, Biomarkers, go-no-go
Single ascending dose (SAD) and multiple ascending dose (MAD) studies are typically the first in human studies. They seek to gain information on safety and tolerability, general pharmacokinetic (PK) and pharmacodynamic ( PD) characteristics, and of course identify the maximum tolerated dose (MTD).
Conventionally, SAD and MAD studies were conducted separately, but increasingly are combined...
Topics: biostatistics, adaptive trials, adaptive designs, Cytel Strategic Consulting, Cytel Consulting, Statistical Programming, Compass, Dose-Finding, Phase 1, Phase I
The Cytel blog keeps you up to speed with the latest developments in biostatistics and clinical biometrics. Sign up for updates direct to your inbox. You can unsubscribe at any time.
Posts by Topic
- biostatistics (96)
- Adaptive Clinical Trials (82)
- Statistical Programming (56)
- Clinical Research Services (50)
- Clinical Development Strategy (47)
- adaptive designs (46)
- Oncology (40)
- Clinical Data (38)
- adaptive trials (35)
- Data Management (31)
- Statistical Analysis (31)
- Bayesian Methods (30)
- clinical trials (27)
- Cytel Strategic Consulting (25)
- Trial Design (23)
- CDISC (22)
- clinical research (21)
- Cytel Consulting (20)
- Early Phase Trials (20)
- Phase 3 (20)
- East (19)
- Interim Analyses (19)
- pharmacometrics (19)
- Phase 1 (18)
- phase 2 (18)
- Regulation (17)
- data manager (17)
- SDTM (16)
- careers (16)
- clinical development (16)
- EAST 6.4 (15)
- EDC (15)
- SAS (15)
- data science (15)
- patient enrollment (15)
- Cyrus Mehta (14)
- Dose-Escalation (14)
- Simulations (13)
- CRO (12)
- Dose-Finding (12)
- FDA (12)
- Program and Portfolio Optimization (12)
- Promising Zone (12)
- Statistical Innovations in Clinical Development (12)
- database build (12)
- pharmacology (12)
- Cardiovascular (11)
- adaptive sample size re-estimation (11)
- Biometrics (10)
- Entrepreneurship (10)
- Recruitment (10)
- ADaM (9)
- Precision Medicine (9)
- big data (9)
- clinical data management (9)
- outsourcing (9)
- Access to Slides PDF (8)
- Bayesian (8)
- CDM (8)
- East 6.3 (8)
- R programming (8)
- Trial Quality (8)
- go-no-go (8)
- sample size re-estimation (8)
- Case Study (7)
- Multi-Arm Multi-Stage Studies (7)
- Multi-Arm Studies (7)
- Phase I (7)
- Software Simulations (7)
- enforesys (7)
- model-informed-drug-development (7)
- BLRM (6)
- DMC (6)
- East ESCALATE (6)
- East PREDICT (6)
- Enrichment (6)
- Nitin Patel (6)
- R language (6)
- Training and Education (6)
- feasibility studies (6)
- quantitative decision-making (6)
- Biomarkers (5)
- Cytel Videos (5)
- MCP-Mod (5)
- Marvin Zelen (5)
- R (5)
- Sample Size (5)
- ACES (4)
- Access to Paper PDF (4)
- CDASH (4)
- CRM (4)
- Exact Tests (4)
- Prediction (4)
- Predictive Enrichment (4)
- Rare Disease (4)
- Rstats (4)
- Safety (4)
- Seamless designs (4)
- Small Sample Sparse Data (4)
- StatXact (4)
- Trial Design Software (4)
- Trial Monitoring (4)
- forecasting (4)
- randomization (4)
- real world evidence (4)
- Cytel Events (3)
- Dose Selection (3)
- Group Sequential (3)
- JSM (3)
- PK/PD (3)
- PSI Conference (3)
- PhUSE (3)
- Proof-of-Concept (3)
- R&D (3)
- Simulation & Biomarkers (3)
- Statistical Puzzles (3)
- White Paper (3)
- basket trials (3)
- custom software (3)
- exact statistics (3)
- genetic algorithm (3)
- meta-analysis (3)
- optimization (3)
- p value (3)
- type 1 error (3)
- Adaptive Finance (2)
- Blind and Unblind Trials (2)
- Compass (2)
- Computing (2)
- EMA (2)
- Education (2)
- Efficacy (2)
- Lingyun Liu (2)
- Medical Devices (2)
- Monte Carlo (2)
- Movers & Shapers (2)
- NONMEM (2)
- PMDA (2)
- Pediatric (2)
- biomedical signals (2)
- estimands (2)
- machine learning (2)
- patientricity (2)
- personalized medicine (2)
- pharmacovigilance (2)
- psychiatry and neuroscience (2)
- signal detection (2)
- trial planning (2)
- Adaptive Licensing (1)
- Antibiotic resistance (1)
- Biosimilars (1)
- Composite Endpoints (1)
- Cytel CliPLab (1)
- Cytel Congratulates (1)
- East Recruit (1)
- Eearly Development (1)
- Evidence Based Medicine (1)
- Exact Inference (1)
- Exact tests for categorical data (1)
- FMCG (1)
- Fourier (1)
- HTA (1)
- ISE (1)
- ISS (1)
- Infectious Diseases (1)
- NICE (1)
- PIPE (1)
- Predicted Interval Plots (1)
- RFP (1)
- Richard Branson (1)
- Risk Based Monitoring (1)
- Sam Hsaio (1)
- Scope conference (1)
- Statistics Article full PDF (1)
- Translational Medicine (1)
- Translational Statistics (1)
- Webinar Slides (1)
- What are... (1)
- benefit risk assessment (1)
- feature selection (1)
- health economics (1)
- immunotherapy (1)
- infographic (1)
- medical ethics (1)
- medical writing (1)
- non parametric analysis (1)
- pattern recognition (1)
- permutations (1)
- population enrichment (1)
- signal processing (1)
- statistical communication (1)
- subgroup analysis (1)
- t-tests (1)
- time to event trials (1)
- time-to-even trials (1)
- treatment switch (1)
- webinar (1)